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Abstract
Background We report dose-escalation results from an open-label, phase 1/2 trial evaluating avelumab (anti-PD-L1) in
paediatric patients with refractory/relapsed solid tumours.
Methods In phase 1, patients aged < 18 years with solid (including central nervous system [CNS]) tumours for which standard therapy did not exist or had failed were enrolled in sequential cohorts of 3–6 patients. Patients received avelumab 10 or
20 mg/kg intravenously every 2 weeks. Primary endpoints were dose-limiting toxicities (DLTs) and grade ≥ 3 treatmentemergent adverse events (AEs).
Results At data cut-off (27 July 2021), 21 patients aged 3–17 years had received avelumab 10 mg/kg (n = 6) or 20 mg/
kg (n = 15). One patient had three events that were classified as a DLT (fatigue with hemiparesis and muscular weakness
associated with pseudoprogression; 20 mg/kg cohort). Grade ≥ 3 AEs occurred in five (83%) and 11 (73%) patients in the
10 and 20 mg/kg cohorts, respectively, and were treatment-related in one patient (7%; grade 3 [DLT]) in the 20 mg/kg
cohort. Avelumab exposure in paediatric patients receiving 20 mg/kg dosing, but not 10 mg/kg, was comparable or higher
compared with approved adult dosing (10 mg/kg or 800 mg flat dose). No objective responses were observed. Four patients
with CNS tumours (20 mg/kg cohort) achieved stable disease, which was ongoing in two patients with astrocytoma at cutoff (for 24.7 and 30.3 months).
Conclusion In paediatric patients with refractory/relapsed solid tumours, avelumab monotherapy showed a safety profile
consistent with previous adult studies, but clinical benefits were limited.
Keywords Avelumab · Paediatrics · Phase 1 · Immunotherapy · Immune checkpoint inhibitor
Abbreviations
AE	Adverse event
AUC	Area under the concentration–time curve
CNS	Central nervous system
Ctrough	Trough serum concentration
DLT	Dose-limiting toxicity
GI	Gastrointestinal
H&E	Haematoxylin and eosin
ICI	Immune checkpoint inhibitor
IRR	Infusion-related reaction
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irRECIST	Immune-related Response Evaluation Criteria
in Solid Tumours
MedDRA	Medical Dictionary for Regulatory Activities
MRI	Magnetic resonance imaging
MTD	Maximum tolerated dose
NE	Not estimable
OS	Overall survival
PD	Progressive disease
PFS	Progression-free survival
PK	Pharmacokinetic
Q2W	Every 2 weeks
RECIST	Response Evaluation Criteria in Solid
Tumours
SD	Stable disease
SMC	Safety Monitoring Committee
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TRAE	Treatment-related adverse event
WHO	World Health Organization

Introduction
Treatment of advanced paediatric cancer typically includes
cytotoxic chemotherapy; however, patients often develop
resistance and have refractory or relapsed disease, resulting in a poor prognosis [1, 2]. Immune checkpoint inhibitors (ICIs) that target the PD-L1/PD-1 interaction have
been approved as treatments for various adult cancers.
Recently, several early phase trials investigating ICI monotherapy specifically in paediatric cancers have shown
acceptable safety profiles but low antitumour activity,
except in Hodgkin lymphoma [3–5].
Avelumab, an anti-PD-L1 antibody, has shown clinical
activity in various tumours [6–10]. Avelumab is approved
in various countries for the treatment of metastatic Merkel cell carcinoma (including patients aged ≥ 12 years in
the USA) in addition to platinum-treated urothelial carcinoma (first-line maintenance therapy or second-line therapy) and advanced renal cell carcinoma (first-line treatment in combination with axitinib) [11]. Avelumab was
initially approved with 10-mg/kg dosing every 2 weeks
(Q2W), but this was subsequently changed to a flat dose of
800 mg in the USA, Europe, and other locations, based on
pharmacokinetic (PK) studies [12]. Other ICIs approved
specifically for paediatric patients are pembrolizumab (in
primary mediastinal large B-cell lymphoma, microsatellite instability—high cancers, tumour mutational burden—
high cancers, and Merkel cell carcinoma in the USA, and
relapsed/refractory classical Hodgkin lymphoma in the
USA and Europe) and nivolumab (alone or combined with
ipilimumab in microsatellite instability—high metastatic
colorectal cancer in the USA) [13, 14]. Except for Hodgkin
lymphoma, ICI approvals in paediatric populations have
generally been based on paediatric safety/PK analyses and
efficacy findings in adults [13, 14].
We report dose-escalation results from a trial of avelumab monotherapy in paediatric patients with refractory
or relapsed solid tumours.

Methods
Study design and participants
In phase 1 of this international, open-label, multicentre,
single-arm, phase 1/2 trial (registered at clinicaltrials.gov:
NCT03451825), eligible patients were aged < 18 years
at first dose and had a histologically or cytologically
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confirmed diagnosis of a solid tumour (including central
nervous system [CNS] tumours) or lymphoma that had
progressed with standard therapy or for which no standard
therapy existed. Other eligibility criteria included Lansky
(≤ 16 years) or Karnofsky (> 16 years) performance status ≥ 50; estimated life expectancy > 3 months; adequate
haematologic, hepatic, and renal function; availability of
recently obtained tumour tissue; negative pregnancy test
(in all postmenarcheal females, females aged ≥ 10 years, or
per local guidelines); and use of effective contraception (in
patients who were considered to be biologically capable of
having children and were sexually active). Exclusion criteria included rapidly progressive disease (PD), grade ≥ 3
neuropathy, known congenital immunodeficiency, prior
therapy targeting a T-cell coregulatory protein, active
autoimmune disease that might deteriorate when receiving
an immunostimulatory agent (not including diabetes type
1, vitiligo, psoriasis, or hypothyroid/hyperthyroid disease
not requiring immunosuppressive treatment), and serious
cardiovascular disease or other severe medical conditions. Use of systemic steroids was tapered before study
treatment except for adrenal insufficiency (physiological
replacement dose permitted) or acute allergy (≤ 14 days
permitted).
The trial was conducted in accordance with the ethics
principles of the Declaration of Helsinki and the International Council for Harmonisation Guideline for Good Clinical Practice. The protocol was approved by the institutional
review board or independent ethics committee of each centre. All patients or legal representatives of patients provided
written informed consent before enrolment.

Procedures
Sequential cohorts of three to six patients were enrolled. The
avelumab starting dose was 10 mg/kg by 1-h intravenous
infusion Q2W. Escalation to, but not exceeding, 20 mg/kg
intravenously Q2W was planned if exposure was inadequate
compared with adult exposures derived from population PK
simulations (maximum serum concentration, area under the
concentration–time curve [AUC], and trough serum concentration [Ctrough]). To mitigate the potential for infusionrelated reactions (IRRs), a known adverse event (AE) with
avelumab [15], antihistamine (e.g. diphenhydramine) and
paracetamol premedication, dosed per local treatment
standards, was mandatory 30 to 60 min before the first four
infusions.
AEs were coded using Medical Dictionary for Regulatory
Activities (MedDRA) version 22.1 and graded according to
the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03. Dose-limiting toxicity
(DLT) was defined as any of the following events occurring during the DLT observation period (first two cycles of

Cancer Immunology, Immunotherapy

treatment [28 days]) if considered related to avelumab: grade
4 neutropenia (> 7 days), thrombocytopenia (> 7 days), or
anaemia; grade ≥ 3 neutropenic infection or thrombocytopenia with bleeding; or specified grade ≥ 3 nonhaematologic
toxicities excluding those that resolved and/or were without
clinical correlate. Inability to complete two or more avelumab infusions during the DLT period due to treatmentrelated toxicity was also classified as a DLT. All safety data
were reviewed by the Safety Monitoring Committee (SMC)
for potential DLTs at predefined intervals. The maximum
tolerated dose (MTD) was defined as the highest dose level
at which < 33% of evaluable patients experienced a DLT,
provided that a higher dose level was tested and had an associated DLT rate ≥ 33%. Immune-related AEs were evaluated
using a customised list of MedDRA terms and by investigator assessment using a predefined medical algorithm. IRRs
were identified using prespecified lists of MedDRA terms in
association with time of onset and resolution.
Patients received avelumab until confirmed PD per
immune-related Response Evaluation Criteria in Solid
Tumours (irRECIST), death, unacceptable toxicity, or withdrawal of consent. Treatment could continue after confirmed
PD if the patient had no new or worsening symptoms, was
tolerating avelumab, had stable performance status, and
treatment would not delay preventive intervention for serious
complications of PD. Tumours were assessed radiologically
at baseline, every 8 weeks for 24 weeks, then every 12 weeks
thereafter. Objective tumour response was evaluated by
investigators per RECIST version 1.1. For some analyses,
patients were assigned to subgroups of CNS tumours, sarcomas, and gastrointestinal (GI) tumours.
Blood samples for PK analysis were collected during
treatment cycles 1, 2, 3, 5, 7, 8, 13, and every 6 cycles
thereafter. Serum avelumab concentrations were analysed
by immunoassay. PK parameters were calculated by noncompartmental analysis.
PD-L1 expression was assessed in baseline tumour tissue
using the PD-L1 73–10 immunohistochemistry assay (Dako,
Carpinteria, California, USA). PD-L1+ status was defined
as PD-L1 expression on tumour cells at any intensity with
cut-offs of ≥ 1%, ≥ 5%, ≥ 25%, ≥ 50%, or ≥ 80%.

Statistical analysis

Outcomes

Safety

Primary endpoints in phase 1 were DLTs in the DLT observation period, to determine the recommended phase 2 dose,
and grade ≥ 3 treatment-emergent AEs. Secondary endpoints
included confirmed best overall response and progressionfree survival (PFS) per RECIST 1.1 by investigator assessment; overall survival (OS); safety; and single/multiple-dose
PK profiles.

One patient in the 20 mg/kg cohort was not included in
the DLT analysis because they received only one dose of
avelumab owing to an AE. Of the remaining 20 patients
(10 mg/kg, n = 6; 20 mg/kg, n = 14), 18 completed the DLTevaluable period, whereas two patients stopped treatment
after receiving two doses of avelumab due to PD, who,
therefore, were nonevaluable for DLTs. One patient (8%)
in the 20 mg/kg cohort with a high-grade glioma experienced three concurrent events (fatigue with hemiparesis

Efficacy and safety were analysed in all patients who
received at least one avelumab dose. DLTs were evaluated in all patients who received all assigned trial treatment administrations in the DLT evaluation period or who
stopped treatment because of DLTs in this period. Planned
enrolment was 12 to 36 patients in phase 1 using the modified toxicity probability interval approach [16]. At least 12
DLT-evaluable patients, treated at a dose level confirmed to
be safe, were required for the primary analysis. Two-sided
95% CIs for objective response rates were calculated using
the Clopper–Pearson method. Time-to-event endpoints were
estimated using the Kaplan–Meier method, and corresponding two-sided CIs for medians were calculated using the
Brookmeyer–Crowley method.

Results
Patients
Twenty-one patients with various advanced solid tumours
were enrolled. Most patients (71%) were Asian. Median age
was 12.0 years (range 3–17), and median weight was 37.3 kg
(range 13.4–78.7). Patients received avelumab 10 mg/kg
(n = 6) or 20 mg/kg (n = 15) Q2W (Table 1). Tumour subgroups were CNS in eight (all 20 mg/kg cohort), sarcoma
in 12 (10 mg/kg [n = 5] and 20 mg/kg [n = 7] cohorts), and
GI in one (colon cancer; 10 mg/kg cohort). No patients with
lymphoma were enrolled. All patients had received prior
therapy; nine patients (43%) had received four or more prior
lines of therapy (Table 1).
Median duration of treatment was 8.2 weeks (range
6.1–15.9) in the 10 mg/kg cohort and 11.9 weeks (range
2.0–134.1) in the 20 mg/kg cohort, and median follow-up
was 18.8 weeks (range 6.4–62.3) and 30.1 weeks (range
3.6–139.0), respectively. At data cut-off (27 July 2021), no
patient remained on treatment (Fig. 1). The most common
reason for discontinuation was PD (10 mg/kg, n = 5 [83%];
20 mg/kg, n = 7 [47%]) (Fig. 1).
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Table 1  Baseline characteristics
Avelumab 10 mg/kg (n = 6)
Sex, n (%)
Male
4 (67)
Female
2 (33)
Race, n (%)
Asian
6 (100)
White
0
Data not collected
0
Geographical region, n (%)
North America
0
Western Europe
0
Asia
6 (100)
Median age, years (range)
12.5 (8–15)
Age category, n (%)
1–12 years
3 (50)
> 12 years
3 (50)
Median weight, kg (range)
34.6 (18.5–65.6)
Primary tumour category, n (%)
Central nervous system
0
Soft tissue/bone sarcoma
5 (83)
Gastrointestinal (colon cancer)
1 (17)
Median time since initial cancer diagnosis,
21.1 (4.5–60.2)
months (range)
Median time since diagnosis of metastatic
14.5 (2.6–29.7)
disease, months (range)
Disease stage at study entry, n (%)
I
0
II
0
III
1 (17)
IV
5 (83)
Missing
0
Prior anticancer surgery, n (%)
6 (100)
Prior anticancer radiotherapy, n (%)
3 (50)
No. of prior anticancer drug regimens, n (%)
0
0
1
1 (17)
2
0
3
1 (17)
≥4
4 (67)
Best overall response to prior anticancer therapy, n (%)a
Complete response
0
Partial response
0
Stable disease
2 (33)
Progressive disease
3 (50)
Not evaluable
1 (17)
Unknown
0
a

Avelumab 20 mg/kg (n = 15)

All patients (N = 21)

7 (47)
8 (53)

11 (52)
10 (48)

9 (60)
4 (27)
2 (13)

15 (71)
4 (19)
2 (10)

5 (33)
1 (7)
9 (60)
12.0 (3–17)

5 (24)
1 (5)
15 (71)
12.0 (3–17)

8 (53)
7 (47)
37.3 (13.4–78.7)

11 (52)
10 (48)
37.3 (13.4–78.7)

8 (53)
7 (47)
0
24.1 (4.3–168.0)

8 (38)
12 (57)
1 (5)
22.2 (4.3–168.0)

6.2 (0.3–53.5)

10.3 (0.3–53.5)

0
1 (7)
0
8 (53)
6 (40)
15 (100)
7 (47)

0
1 (5)
1 (5)
13 (62)
6 (29)
21 (100)
10 (48)

0
2 (13)
7 (47)
1 (7)
5 (33)

0
3 (14)
7 (33)
2 (10)
9 (43)

1 (7)
2 (13)
0
8 (53)
0
4 (27)

1 (5)
2 (10)
2 (10)
11 (52)
1 (5)
4 (19)

If a patient had received more than one prior anticancer therapy, best overall response to last therapy received is reported

and muscular weakness associated with pseudoprogression;
all grade 3) that were assessed as a DLT by the SMC. The
MTD was not reached. During the DLT evaluation period,
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treatment-emergent AEs of any grade or causality occurred
in all six patients (100%) in the 10 mg/kg cohort and 11
of 12 patients (92%) in the 20 mg/kg cohort, including
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26 patients assessed for eligibility
5 excluded before treatment
4 eligibility criteria not met
1 withdrawal
21 enrolled and treated with avelumab

6 treated with avelumab 10 mg/kg

6 discontinued avelumab
5 disease progression
1 withdrawal

15 treated with avelumab 20 mg/kg

15 discontinued avelumab
1 died
7 disease progression
5 adverse events
1 withdrawal
1 other reasons
0 treatment ongoing

0 treatment ongoing

6 analysed for efficacy and safety outcomes

15 analysed for efficacy and safety outcomes

6 analysed for DLTs

12 analysed for DLTs

Fig. 1  Trial profile. DLT, dose-limiting toxicity

grade ≥ 3 AEs in one patient (17%) and two patients (17%),
respectively.
In the full patient group, AEs of any grade occurred in
all 21 patients, including grade ≥ 3 AEs in five patients
(83%) in the 10 mg/kg cohort and 11 patients (73%) in the
20 mg/kg cohort (Table 2). The most common grade ≥ 3 AEs
(≥ 30%) were abdominal pain (n = 2 [33%]) in the 10 mg/kg
cohort and disease progression (n = 5 [33%]) in the 20 mg/
kg cohort. In the 10 and 20 mg/kg cohorts, serious AEs of
any grade occurred in four patients (67%) and 12 patients
(80%), respectively. AEs led to discontinuation in patients
in the 20 mg/kg cohort only (n = 8 [53%]), including disease progression (n = 5 [33%]), and thrombocytopenia (n = 1
[7%]), malignant pleural effusion (n = 1 [7%]), and intracranial pressure increased (n = 1 [7%]), all three of which
were related to disease progression. AEs resulted in death in
one patient (17%) in the 10 mg/kg cohort and three patients
(20%) in the 20 mg/kg cohort, all due to disease progression.
Treatment-related AEs (TRAEs) of any grade occurred in
three patients (50%) in the 10 mg/kg cohort and 10 patients
(67%) in the 20 mg/kg cohort (Supplementary Table 1). The
most common TRAEs (≥ 20%) in the 20 mg/kg cohort were
fatigue (n = 4 [27%]), nausea (n = 3 [20%]), and chills (n = 3
[20%]); no TRAE occurred in more than one patient in the
10 mg/kg cohort. Grade 3 TRAEs occurred in one patient
(7%) in the 20 mg/kg cohort (fatigue, hemiparesis, muscle
weakness, and tumour pseudoprogression; patient with
DLT described above). No grade 4 or 5 TRAEs occurred,

and none led to discontinuation. An immune-related AE
occurred in one patient (7%) in the 20 mg/kg cohort (grade
2 hypothyroidism). Grade 1/2 IRRs occurred in two patients
(33%) in the 10 mg/kg cohort and seven patients (47%) in the
20 mg/kg cohort; no grade ≥ 3 IRRs occurred.

PK
In PK analyses (N = 21; data cut-off, 21 October 2019), the
median and geometric mean of the AUC and C
 trough for cycle
1 in the 10 mg/kg cohort appeared lower vs approved adult
dosing, particularly in patients with a body weight of < 40 kg
(Table 3). The median and geometric mean of the AUC and
Ctrough for cycle 1 in the 20 mg/kg cohort were similar or
higher vs adult values with approved dosing, irrespective
of body weight. No clear association was observed between
age and exposure in either dose cohort. Additionally, the PK
profile in the patient with DLT was similar to other patients
in the same dose cohort (20 mg/kg) and adults treated with
approved dosing.

Efficacy
No objective responses were observed (Supplementary
Tables 2 and 3). No patient had a reduction in the sum of
target lesions (Fig. 2; Supplementary Fig. 1), and no trend
in type of progression (i.e. target vs nontarget vs new lesion)
was observed (Supplementary Table 4). Four patients in the
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Table 2  Treatment-emergent adverse events
Avelumab 10 mg/kg
(n = 6)

Avelumab 20 mg/kg
(n = 15)

Any grade Grade ≥ 3 Any grade Grade ≥ 3
Any AE, n (%)
Pyrexia
Anaemia
Abdominal pain
Disease progression
Dyspnoea
Hyponatraemia
Vomiting
Back pain
Constipation
Hypoalbuminemia
Arthralgia
Chills
Hypotension
Fatigue
Nausea
Headache
Pain in extremity
Hypophagia
Nasopharyngitis
Procedural pain
Pruritus
Hypertension

6 (100)
4 (67)
2 (33)
2 (33)
1 (17)

5 (83)
0
1 (17)
2 (33)
1 (17)

15 (100)
10 (67)
5 (33)
3 (20)
5 (33)

11 (73)
0
1 (7)
0
5 (33)

1 (17)
1 (17)
1 (17)
1 (17)
1 (17)
1 (17)

1 (17)
1 (17)
0
0
0
0

3 (20)
2 (13)
6 (40)
4 (27)
5 (33)
4 (27)

1 (7)
2 (13)
0
1 (7)
0
0

1 (17)
1 (17)
1 (17)
0
0
0
0
0
0
0
0
0

0
0
0
0
0
0
0
0
0
0
0
0

3 (20)
3 (20)
3 (20)
6 (40)
6 (40)
5 (33)
4 (27)
3 (20)
3 (20)
3 (20)
3 (20)
2 (13)

1 (7)
0
0
1 (7)
1 (7)
1 (7)
0
2 (13)
0
0
0
2 (13)

AEs of any grade occurring in three or more patients or grade ≥ 3 in
two or more patients in either cohort are shown
AE, treatment-emergent adverse event

20 mg/kg cohort had stable disease (SD). The disease control rate (proportion with confirmed response or SD) was
0% (95% CI, 0–46) in the 10 mg/kg cohort and 27% (95%
CI, 8–55) in the 20 mg/kg cohort. All four patients who had
SD had a CNS tumour: astrocytoma of the spinal cord, pilocytic astrocytoma, pilomyxoid astrocytoma (all low grade),
and H3 K27M-mutant diffuse midline glioma. Duration of
SD ranged from 2.4 to 30.3 months and was ongoing at last
assessment (data cut-off, 27 July 2021) in two patients with
astrocytoma after 30.3 and 24.7 months (Supplementary
Fig. 2A). Prestudy target lesion data suggested that these
tumours were growing slowly prior to study entry (Supplementary Fig. 2B). Prior systemic treatment or radiotherapy
and site of primary tumour were not associated with clinical
benefit from avelumab (Supplementary Table 5).
Median PFS was 7.5 weeks (95% CI, 6.6–not estimable [NE]) in the 10 mg/kg cohort and 7.7 weeks (95%
CI, 2.3–10.3) in the 20 mg/kg cohort (Supplementary
Fig. 3A); median OS was 4.4 months (95% CI, 1.5–NE)
and 7.0 months (95% CI, 1.6–10.8), respectively (Supplementary Fig. 3B).

Biomarker analyses
A total of 15 patients were evaluable for PD-L1 expression
(Supplementary Table 6). Using a ≥ 1% cut-off to define
PD-L1+ status, five patients (33%) had PD-L1+ tumours and
10 (67%) had PD-L1− tumours. Notably, the two patients
with astrocytoma who had prolonged and ongoing SD with
avelumab treatment had tumours with high PD-L1+ expression at baseline (≥ 80% of tumour cells; Fig. 3). The other
three patients with PD-L1+ tumours all had PD as their best
overall response with avelumab.

Table 3  PK summary following first infusion of cycle 1 of avelumab in paediatric patients, with adult data shown for comparison
Dose cohort, body
weight category

Patients, n

800 mg, adults
10 mg/kg, all patients
10 mg/kg, < 40 kg
10 mg/kg, ≥ 40 kg
20 mg/kg, all patients
20 mg/kg, < 40 kg
20 mg/kg, ≥ 40 kg

10,000
6
4
2
15 (14 for C
 trough)
10
5 (4 for Ctrough)

Cmax, µg/mL

AUC0-336, µg·h/mL

Ctrough, µg/mL

Geometric
mean

Geometric
CV, %

Geometric mean

Geometric
CV, %

Geometric mean

Geometric
CV, %

256
190
157
281
384
338
496

25.6
34.5
16.2
16.9
27.3
20.4
19.4

24,486
18,800
16,000
25,700
42,800
41,400
45,900

27.7
29.2
19.1
7.3
22.1
21.8
23.7

17.2
11.2
8.8
18.3
34.8
39.4
25.5

68
44.9
23.6
20
77.8
70.1
97.5

 max, maximum serum concentration; C
 trough, trough serum concentraAUC0-336, area under the concentration–time curve from time 0 to 336 h; C
tion; CV, coefficient of variation; and PK, pharmacokinetic
Data cut-off, 21 October 2019
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Change in target
lesions from baseline (%)

A

200

End of treatment
New lesion
Nontarget PD

150
100
50
0
0

20

40

60

80

100

120

140

Weeks
10 mg/kg

Change in target
lesions from baseline (%)

B

20 mg/kg

200

End of treatment
New lesion
Nontarget PD

150
100
50
0
0

20

40

60

80

100

120

140

Weeks

Fig. 2  Change in target lesions per RECIST 1.1 from baseline over
time in evaluable patients (those with baseline and postbaseline data):
A all evaluable patients (n = 18); B patients with central nervous sys-

tem tumours (n = 7). Increases greater than 200% are shown as 200%.
PD, progressive disease; RECIST 1.1, Response Evaluation Criteria
in Solid Tumours version 1.1

Discussion

and 47% in the 20 mg/kg cohort, and no grade ≥ 3 IRRs
occurred. These rates appear higher than those seen in studies of avelumab in adults, although this may be due to the
small sample size in the paediatric study [15]. The frequency
of IRRs in this study was also higher than reported for other
ICIs in trials in paediatric patients, although it should be
noted that trials of other ICIs used narrower definitions for
IRR [3, 4]. No new safety signals were observed in paediatric patients, and the frequency and severity of AEs were
generally consistent with adult studies [15].
PK analysis showed that paediatric dosing with 10 mg/
kg resulted in lower exposure vs adults receiving approved
dosing (10 mg/kg or 800 mg Q2W), particularly in patients
weighing < 40 kg (i.e. those receiving the lowest dose). However, 20 mg/kg Q2W dosing achieved or exceeded exposures
in adults, irrespective of body weight. PK analyses from
this study, in addition to subsequent modelling and simulation approaches, have been used to select the recommended
dose for future avelumab studies in paediatric patients of

Avelumab monotherapy had an acceptable safety profile in
paediatric patients at both dose levels investigated, 10 mg/
kg and 20 mg/kg Q2W, with a low incidence of grade ≥ 3
TRAEs and no grade ≥ 3 immune-related AEs. One patient
treated with 20 mg/kg had three concurrent events that were
assessed as a DLT but were likely associated with tumour
pseudoprogression, a known phenomenon with ICI treatment [17] that may not be dose dependent. The MTD was
not reached, which has been a common finding in ICI trials
and reflects the challenges of dose evaluation using study
designs adopted initially for cytotoxic agents. Grade ≥ 3 AEs
occurred in 83% in the 10 mg/kg cohort and 73% in the
20 mg/kg cohort, but grade ≥ 3 AEs were considered treatment-related only in one patient (DLT; 20 mg/kg cohort),
and no grade 4/5 TRAEs occurred. All AEs that led to
discontinuation were associated with disease progression.
Grade 1/2 IRRs occurred in 33% in the 10 mg/kg cohort
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Fig. 3  Histological images of H&E and PD-L1 (73–10) staining of ▸
tumour samples for the two patients with astrocytoma who had prolonged SD (> 24 months) with avelumab. Both patients had tumours
with ≥ 80% of tumour cells having membrane staining positive for
PD-L1 expression. Patient A (female aged 9 years) had a pilocytic
astrocytoma (WHO grade I). The patient presented in 2018 with a
mass at the cerebellopontine angle and upper cervical spine showing cystic and contrast-enhancing solid portions via MRI scan. Histopathology showed an astrocytic tumour with increased cellularity,
mild pleomorphism, low mitotic activity (2/10 high-power fields),
and absent necrosis. Immunophenotype was positive for glial fibrillary acidic protein and strong PD-L1 expression in tumour cells but
not tumour vessels (arrow). The tumour was B
 RAFV600E mutationpositive, but no PTEN deletion or MGMT promoter methylation was
present. The patient underwent surgery in April 2018 with residual
tumour and received vincristine + carboplatin from May to July 2018
(best overall response of PD) followed by thioguanine + procarbazine + lomustine in August 2018 (best overall response unknown);
no radiation was administered. The patient received avelumab treatment from October 2018 until April 2021, and tumour size changed
over time from 40 to 45 mm. Lansky performance status improved
from 50% at study entry to 70% with avelumab treatment, and the
patient discontinued from the study to receive subsequent anticancer
therapy (surgery). Patient B (male aged 3 years) had an astrocytoma
of spinal cord (WHO grade II; NF1-associated). The patient presented in 2018 with a contrast-enhancing intramedullary mass at the
upper thoracic spinal cord (MRI). Microscopy showed a tumour with
increased cellularity, mild pleomorphism, low mitotic activity (1/10
high-power field), absent microvascular proliferation, and absent
necrosis. Immunophenotype was positive for glial fibrillary acidic
protein and synaptophysin, and strong PD-L1 expression was seen
in tumour cells but not tumour vessels (arrow). The tumour had an
NF1 mutation (p.Gln1577*, c.4729C > T), but no mutations of BRAF
(V600E), IDH1, TP53, or PTEN were present. In 2021, the tumour
was classified as ganglioglioma, WHO grade I. The patient had surgery with residual tumour in July 2018 and received vincristine + carboplatin from August to November 2018 (best overall response of
PD), with no radiation. The patient received avelumab treatment from
December 2018 until February 2021, and tumour size changed over
time from 12 to 16 mm (not classified as PD according to RECIST
1.1 because the tumour size did not increase by ≥ 5 mm), with Lansky
performance status stable at 90%. The patient discontinued the study
to receive subsequent anticancer therapy (surgery). H&E, haematoxylin and eosin; MRI, magnetic resonance imaging; PD, progressive
disease; RECIST, Response Evaluation Criteria in Solid Tumours;
SD, stable disease; and WHO, World Health Organization

15 mg/kg Q2W for patients < 12 years or < 40 kg and the
adult dose of 800 mg Q2W for paediatric patients ≥ 12 years
and ≥ 40 kg [18].
Antitumour activity of avelumab monotherapy was limited in relapsed or refractory paediatric solid tumours, consistent with other recent studies of ICIs in similar populations [3–5]. Four patients with CNS tumours achieved SD
on study, including two patients with low-grade astrocytoma
who had ongoing SD lasting > 24 months; however, prestudy tumour assessments suggested that these tumours were
growing slowly. The lack of objective responses reported
with several ICIs may be due to differences in tumour
biology between paediatric and adult cancers, including a
lower mutational burden in most paediatric tumours [19],
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and differences in immune responses between adults and
younger patients [20]. Additionally, the enrolled population
had a high proportion of patients who were Asian, which
may have introduced bias. Despite recruitment efforts, no
patients were enrolled with lymphoma, a malignancy that
often responds to ICI monotherapy [3–5]. Limited data
are available on paediatric patients with CNS tumours
treated with other ICIs because trials generally exclude
these patients [4, 5]. In KEYNOTE-051, pembrolizumab
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showed some benefit in paediatric patients with various
PD-L1+ solid tumours, including partial response in a
patient with a malignant ganglioglioma, and tumour shrinkage (< 30% decrease) in patients with high-grade glioma,
glioblastoma, ependymoma, and ganglioneuroblastoma
among other tumours [3]. In this study, two of the three
patients with astrocytoma who had prolonged SD with avelumab had high PD-L1+ tumours (≥ 80%); the other three
patients with PD-L1+ tumours had PD as best response to
avelumab.
This study was part of a paediatric investigation plan
approved by the European Medicines Agency in 2017,
which was originally for the treatment of solid tumours
and was subsequently modified to include lymphomas and
CNS tumours [21]. The trial was initiated, and planned as
a phase 1/2 study, before the updated overall paediatric
strategy for ICIs was agreed upon by ACCELERATE and
the European Medicines Agency at the Paediatric Strategy
Forum in September 2018, which recommended a focus on
combination studies because of the limited activity seen in
several studies with ICI monotherapy [22]. Subsequently, it
was decided not to proceed with phase 2 after the completion of phase 1 of this trial. A future study will investigate
the combination of avelumab plus lenvatinib (a receptor
tyrosine kinase inhibitor) in paediatric patients with CNS
tumours (NCT05081180). This planned trial is supported by
the disease stabilizations observed both in our trial and in a
retrospective study of ICIs [23]. Additionally, in a cohort of
31 adults with previously treated glioblastoma multiforme
who received lenvatinib in combination with pembrolizumab
within a phase 2 trial, an objective response rate of 16% (per
Response Assessment in Neuro-Oncology criteria) and disease control rate of 58% were reported [24], supporting the
evaluation of lenvatinib and avelumab combination therapy
in paediatric patients with CNS tumours.
In conclusion, the tolerability seen with avelumab monotherapy in paediatric patients with previously treated solid
tumours, including those with CNS tumours, supports further studies of avelumab-based combination therapy in these
tumours.
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